{
  "abstract": "Antiretroviral therapy suppresses HIV-1 replication but cannot eliminate the latent viral reservoir persisting in memory CD4 T cells. Existing latency reversal candidates have yet to achieve robust viral reactivation at tolerable doses. We engineered T4IL15{triangleup}, a bispecific biologic that selectively delivers IL-15 signaling to memory CD4 T cells, with minimal off-target stimulation. T4IL15{triangleup} reactivated latent virus in 94% (48/51) of clinical samples ex vivo, 75% (15/20) of administrations in HIV-1-infected and ART-suppressed humanized mice, and 100% (6/6) of SIV-infected and ART-suppressed rhesus macaques at doses well tolerated. We also found that off-target stimulation of non-CD4 cells hindered HIV-1 reactivation ex vivo. T4IL15{triangleup} provides a robust reactivation platform that could complement other reservoir-elimination strategies toward an HIV-1 cure.",
  "abstract_shown": true,
  "affiliations": [
    "Columbia University Vagelos College of Physicians and Surgeons"
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 17,
  "authors": [
    {
      "name": "Y. Huang"
    },
    {
      "name": "M. S. Nair"
    },
    {
      "name": "J. Yu"
    },
    {
      "name": "S. Chong"
    },
    {
      "name": "H. Hong"
    },
    {
      "name": "H. Mohri"
    },
    {
      "name": "H. Takata"
    },
    {
      "name": "B. D. Varco-Merth"
    },
    {
      "name": "A. Marenco"
    },
    {
      "name": "J. D. Lifson"
    },
    {
      "name": "L. Ndhlovu"
    },
    {
      "name": "A. Bowen"
    },
    {
      "name": "L. Trautmann"
    },
    {
      "name": "S. Vasan"
    },
    {
      "name": "T.-W. Chun"
    },
    {
      "name": "A. A. Okoye"
    },
    {
      "affs": [
        0
      ],
      "name": "D. D. Ho"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3bb0rkv317q8h.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.10.06.757104",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.10.06.757104v1.full",
  "id": "3bb0rkv317q8h",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.10.06.757104v1",
  "language": null,
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "microbiology"
    ],
    [
      "openalex",
      "2406|HIV Research and Treatment"
    ]
  ],
  "openalex": "W7220923544",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.10.06.757104v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-06",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/3bb0rkv317q8h.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:26:40Z",
      "native_id": "10.64898/2026.10.06.757104",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.10.06.757104v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "biorxiv:microbiology",
      "subfield": "microbiology"
    }
  ],
  "title": "A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency",
  "title_text": "A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency",
  "type": "preprint",
  "updated_at": "2026-10-30T12:26:40Z",
  "url": "https://research.draconitic.com/paper/3bb0rkv317q8h",
  "venue": "bioRxiv",
  "versions": []
}